MENU
Advertisement
Show Filters
Refine by Content Type
Refine by Year
Sort By:
Choose Sites to Search:
Sponsored by Silk Road Medical
TCAR Limitations: Separating Fact From Fiction
With Rasesh M. Shah, MD, FACS, and Susan M. Shafii, MD, MHSA, FACS, FSVS
Transitioning to the TCAR-First Strategy for Carotid Revascularization
By Rasesh M. Shah, MD, FACS, and H. Edward Garrett Jr, MD, FACS
The Evolution of TCAR Into First-Line Therapy for Carotid Revascularization
By Rasesh M. Shah, MD, FACS
Silk Road Medical Begins ROADSTER 3 Postapproval Study of TCAR System in Patients at Standard Surgical Risk
September 7, 2022—Silk Road Medical, Inc. announced enrollment of the first patient in the ROADSTER 3 postapproval study of the company’s system for transcarotid artery revascularization (TCAR) of patients at standard surgical risk with carotid artery disease in real-world treatment.
